Larimar Therapeutics Past Earnings Performance
Past criteria checks 0/6
Larimar Therapeutics's earnings have been declining at an average annual rate of -7.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-7.8%
Earnings growth rate
36.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -32.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Dec 18
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Oct 07Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans
Aug 09Larimar Therapeutics: More Data Still Needed
Jul 15Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
May 31We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Laramar Therapeutics issued patent for lead pipeline candidate
Oct 20Larimar Therapeutics prices ~$70M stock offering
Sep 14Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02Larimar Therapeutics GAAP EPS of -$0.47
Aug 11We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Larimar under pressure as FDA puts clinical hold on CTI-1601 program
May 26Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 08
Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index
Dec 15Larimar completes dosing in Friedreich’s Ataxia, provides program update
Dec 08Larimar Therapeutics (LRMR) Investor Presentation - Slideshow
Nov 16Larimar Therapeutics reports Q3 results
Nov 10Revenue & Expenses Breakdown
How Larimar Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -65 | 17 | 57 |
| 30 Jun 24 | 0 | -58 | 16 | 50 |
| 31 Mar 24 | 0 | -45 | 15 | 36 |
| 31 Dec 23 | 0 | -37 | 14 | 28 |
| 30 Sep 23 | 0 | -33 | 14 | 24 |
| 30 Jun 23 | 0 | -33 | 13 | 23 |
| 31 Mar 23 | 0 | -33 | 12 | 23 |
| 31 Dec 22 | 0 | -35 | 12 | 24 |
| 30 Sep 22 | 0 | -35 | 12 | 23 |
| 30 Jun 22 | 0 | -44 | 12 | 32 |
| 31 Mar 22 | 0 | -47 | 12 | 35 |
| 31 Dec 21 | 0 | -51 | 12 | 38 |
| 30 Sep 21 | 0 | -56 | 13 | 43 |
| 30 Jun 21 | 0 | -49 | 14 | 36 |
| 31 Mar 21 | 0 | -48 | 13 | 35 |
| 31 Dec 20 | 0 | -42 | 11 | 31 |
| 30 Sep 20 | 0 | -34 | 9 | 26 |
| 30 Jun 20 | 0 | -33 | 6 | 27 |
| 31 Mar 20 | 0 | -25 | 4 | 22 |
| 31 Dec 19 | 0 | -23 | 2 | 21 |
Quality Earnings: LRMR is currently unprofitable.
Growing Profit Margin: LRMR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LRMR is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare LRMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LRMR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LRMR has a negative Return on Equity (-32.65%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 10:55 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Larimar Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Samantha Lynn Semenkow | Citigroup Inc |
| Samantha Lynn Semenkow | Citigroup Inc |